New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul.

Gilead recently shelled out $400 million upfront for an early-stage drug for NASH, the first deal under new CEO Milligan.

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able to gain favorable insurance coverage despite questions about how the Trump ...

“I expect remdesivir with these variants will continue to make an impact on patients,” Gilead Sciences CEO Daniel O’Day told CNBC.

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

John Milligan was the 32nd employee at Gilead Sciences Inc. (IW 500/45) when he was hired as a research scientist in 1990. Now, he’s at the helm of the biggest biotechnology firm in the world, charged ...